Investigative Landscape in Advanced Non-Melanoma Skin Cancers

被引：2

作者：

Reddy, Priyanka ^{[1
]}

Yao, Min ^{[2
]}

Patel, Monaliben ^{[3
]}

机构：

[1] Case Comprehens Canc Ctr, Dept Hematol & Oncol, Dept Radiat Oncol, 11100 Euclid Ave, Cleveland, OH 44106 USA

[2] Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Radiat Oncol, Sch Med, 11100 Euclid Ave, Cleveland, OH 44106 USA

[3] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Dept Oncol, 11100 Euclid Ave, Cleveland, OH 44106 USA

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2021年 / 22卷 / 07期

关键词：

Squamous cell skin cancer; Basal cell skin cancer; Cutaneous malignancy; Metastatic non-melanoma skin cancer; cemiplimab; pembrolizumab; SQUAMOUS-CELL CARCINOMA; METASTATIC BASAL-CELL; ORGAN TRANSPLANT RECIPIENTS; RANDOMIZED CONTROLLED-TRIAL; PHASE-II; HIGH-RISK; INTERFERON-ALPHA; DOUBLE-BLIND; OPEN-LABEL; PREVENTION;

D O I：

10.1007/s11864-021-00853-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Opinion Statement Advanced non-melanoma skin cancers have been challenging to treat due to limited treatment options. Treatment paradigm has shifted with the approval of immunotherapeutic agents cemiplimab and pembrolizumab which have been a key development and have changed the landscape of advanced or metastatic squamous cell skin cancers. Hedgehog inhibitors, vismodegib and sonidegib, remain upfront options for advanced or metastatic basal cell carcinomas. Current clinical trials are continuing to evaluate the use of immune checkpoint inhibitors and hedgehog pathway inhibitors. There is further need for ongoing research and development of new therapies in both malignancies.

引用

页数：13

共 83 条

[1] Primary care: Cutaneous squamous-cell carcinoma [J].

Alam, M ;

Ratner, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (13) :975-983

[2]

[Anonymous], NCCN CLIN PRACTICE G

[3] Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs) [J].

Asgari, Maryam M. ;

Arron, Sarah T. ;

Warton, E. Margaret ;

Quesenberry, Charles P., Jr. ;

Weisshaar, Dana .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (03) :444-450

[4] Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial [J].

Basset-Seguin, N. ;

Hauschild, A. ;

Kunstfeld, R. ;

Grob, J. ;

Dreno, B. ;

Mortier, L. ;

Ascierto, P. A. ;

Licitra, L. ;

Dutriaux, C. ;

Thomas, L. ;

Meyer, N. ;

Guillot, B. ;

Dummer, R. ;

Arenberger, P. ;

Fife, K. ;

Raimundo, A. ;

Dika, E. ;

Dimier, N. ;

Fittipaldo, A. ;

Xynos, I. ;

Hansson, J. .

EUROPEAN JOURNAL OF CANCER, 2017, 86 :334-348

[5] Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab [J].

Berliner, Jacqueline G. ;

Schulman, Joshua M. ;

Lazarova, Zelmira ;

Olasz, Edit ;

Arron, Sarah T. .

DERMATOLOGIC SURGERY, 2019, 45 (02) :313-316

[6] Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases [J].

Blum, Veronika ;

Mueller, Beat ;

Hofer, Silvia ;

Pardo, Esther ;

Zeidler, Kristin ;

Diebold, Joachim ;

Strobel, Klaus ;

Brand, Christoph ;

Aebi, Stefan ;

Gautschi, Oliver .

EUROPEAN JOURNAL OF DERMATOLOGY, 2018, 28 (01) :78-81

[7] Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases [J].

Borradori, L. ;

Sutton, B. ;

Shayesteh, P. ;

Daniels, G. A. .

BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (06) :1382-1386

[8]

Breithaupt Andrew D, 2015, JAAD Case Rep, V1, pS16, DOI 10.1016/j.jdcr.2015.09.009

[9] Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer [J].

Campbell, S. B. ;

Walker, R. ;

Tai, S. See ;

Jiang, Q. ;

Russ, G. R. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (05) :1146-1156

[10]

Cannon John G D, 2018, JAAD Case Rep, V4, P248, DOI 10.1016/j.jdcr.2018.01.015

← 1 2 3 4 5 6 7 8 9 →